The South West Area Mesothelioma and Pemetrexed trial: A multicentre prospective observational study evaluating novel markers of chemotherapy response and prognostication

British Journal of Cancer

Volumn 112, Issue 7, 2015, Pages 1175-1182

  Hooper, C E ^a,b   Lyburn, I D ^c   Searle, J ^c   Darby, M ^d   Hall, T ^e   Hall, D ^c   Morley, A ^b   White, P ^f   Rahman, N M ^g   De Winton, E ^e   Clive, A ^a   Masani, V ^e   Arnold, D T ^a   Dangoor, A ^h   Guglani, S ⁱ   Jankowska, P ^j   Lowndes, S A ^k   Harvey, J E ^b   Braybrooke, J P ^h   Maskell, N A ^a,b  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

^c Cobalt Health   (United Kingdom)

^d NORTH BRISTOL NHS TRUST   (United Kingdom)

^e ROYAL UNITED HOSPITAL   (United Kingdom)

^f UNIVERSITY OF THE WEST OF ENGLAND   (United Kingdom)

^g CHURCHILL HOSPITAL   (United Kingdom)

^h BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

ⁱ CHELTENHAM GENERAL HOSPITAL   (United Kingdom)

^j MUSGROVE PARK HOSPITAL   (United Kingdom)

^k GREAT WESTERN HOSPITAL   (United Kingdom)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CISPLATIN; FIBULIN; FIBULIN 3; MESOTHELIN; PEMETREXED; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; GLUTAMIC ACID DERIVATIVE; GUANINE; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER SURVIVAL; COHORT ANALYSIS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPHIL LYMPHOCYTE RATIO; OBSERVATIONAL STUDY; OVERALL SURVIVAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROSPECTIVE STUDY; QUALITY OF LIFE; TREATMENT RESPONSE; TUMOR DIAGNOSIS; ANALOGS AND DERIVATIVES; BLOOD; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; LUNG NEOPLASMS; LYMPHOCYTE; MESOTHELIOMA; MULTICENTER STUDY; MULTIMODAL IMAGING; NEUTROPHIL; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; SCINTISCANNING; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOMARKERS, TUMOR; CARBOPLATIN; CISPLATIN; COHORT STUDIES; FEMALE; GLUTAMATES; GUANINE; HUMANS; LUNG NEOPLASMS; LYMPHOCYTES; MALE; MESOTHELIOMA; MULTIMODAL IMAGING; NEUTROPHILS; PEMETREXED; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 84938548483     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.62     Document Type: Article

References (29)

1. Armato III SG, Oxnard GR, MacMahon H, Vogelzang NJ, Kindler HL, Kocherginsky M, Starkey A (2004) Measurement of mesothelioma on thoracic CT scans: a comparison of manual and computer-assisted techniques. Med Phys 31: 1105-1115.
2. Arnold DT, Hooper CE, Morley A, White P, Lyburn ID, Searle J, Darby M, Hall T, Hall D, Rahman NM, de Winton E, Clive A, Masani V, Dangoor A, Guglani S, Jankowska P, Lowndes SA, Harvey JE, Braybrooke JP, Maskell NA (2015) The effect of chemotherapy on health related quality of life in mesothelioma - results from the SWAMP trial. Br J Cancer.
3. Byrne MJ, Nowak AK (2004) Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 5: 257-260.
4. Chapman A, Mulrennan S, Ladd B, Muers MF (2009) Population based epidemiology and prognosis of mesothelioma in Leeds, UK. Thorax 63: 435-439.
5. Creaney J, Dick IM, Meniawy TM, Leong SL, Leon JS, Demelker Y, Segal A, Musk AW, Lee YCG, Skates SJ, Nowak AK, Robinson BWS (2014) Comparison of fibulin-3 and mesothelin as markers of malignant mesothelioma. Thorax 69(10): 895-902.
6. Creaney J, Francis RJ, Dick IM, Musk AW, Robinson BW, Byrne MJ, Nowak AK (2010) Serum soluble mesothelin concentrations in malignant pleural mesothelioma: relationship to tumour volume, clinical stage and changes in tumour burden. Am Assoc Cancer Res 17: 1181-1189.
7. Creaney J, Robinson BW (2005) Detection of malignant mesothelioma in asbestos exposed individuals: the potential role of soluble mesothelin-related protein. Haematol Oncol Clin N Am 19: 1025-1040.
8. Engles JM, Quarless SA, Mambo E, Ishimori T, Cho SY, Wahl RL (2006) Stunning and its effect on #sup#3#/sup#H-FDG uptake and key gene expression in breast cancer cells undergoing chemotherapy. J Nucl Med 47: 603-608.
9. Fitzpatrick DR, Peroni DJ, Bielefeldt-Ohmann H (1995) The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am J Respir Cell Mol Biol 12: 455-460.
10. Francis RJ, Byrne MJ, van der Schaaf AA, Boucek JA, Nowak AK, Phillips M, Price R, Patrikeos AP, Musk W, Millward MJ (2007) Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial #sup#18#/sup#F-FDG PET scans. J Nucl Med 48: 1449-1458.
11. Grigoriu BD, Chahine B, Vachani A, Gey T, Conti M, Sterman DH, Marchandise G, Porte H, Albelda SM, Scherpereel A (2008) Kinetics of soluble mesothelin in patients with malignant pleural mesothelioma during treatment. Am J Respir Crit Care Med 179: 950-954.
12. Guntulu A, Metintas M, Metintas S, Yildirim H, Ozkan R, Ozden H (2010) Three-dimensional evaluation of chemotherapy response in malignant pleural mesothelioma. Eur J Radiol 74: 130-135.
13. Hooper CE, Morley AJ, Virgo P, Harvey JE, Kahan B, Maskell NA (2013) A prospective trial evaluating the role of mesothelin in undiagnosed pleural effusions. Eur Respir 41(1): 18-24.
14. Kao SC, Klebe S, Henderson DW, Reid G, Chatfield M, Armstrong NJ, Yan TD, Vardy J, Clarke S, van Zandwijk N, McCaughan B (2011) Low calretinin expression and high neutrophil-to-lymphocyte ratio are poor prognostic factors in patients with malignant mesothelioma undergoing extrapleural pneumonectomy. J Thorac Oncol 6: 1923-1929.
15. Kao SCH, Pavlakis N, Harvie R, Vardy JL, Boyer MJ, van Zandwijk N (2010) High blood neutrophil-to-lymphocyte ratio is an indicator of poor prognosis in malignant mesothelioma patients undergoing systemic therapy. Clin Cancer Res 16: 5805-5813.
16. Lee HY, Hyun SH, Lee KS, Kim BT, Kim J, Shim YM, Ahn MJ, Kim TS, Yi CA, Chung MJ (2010) Volume-based parameter of #sup#18#/sup#F-FDG PET/CT in malignant pleural mesothelioma: prediction of therapeutic response and prognostic implications. Ann Surg Oncol 17: 2787-2794.
17. Linton A, Pavlakis N, O'Connell RO, Soeberg M, Kao S, Clarke S, Vardy J, van Zandwijk N (2014) Factors associated with survival in a large series of patients with malignant pleural mesothelioma in New South Wales. Br J Cancer 111(9): 1860-1869.
18. NICE (2008) Technology appraisal guidance 135. Pemetrexed for the treatment of malignant pleural mesothelioma.
19. Nowak AK (2005) CT, RECIST, and malignant pleural mesothelioma. Lung Cancer 49S1: S37-S40.
20. Nowak AK, Francis RJ, Phillips MJ, Millward MJ, van der Schaaf AA, Boucek J, Musk AW, McCoy MJ, Segal A, Robins P, Byrne MJ (2010) A novel prognostic model for malignant mesothelioma incorporating quantitative FDG-PET imaging with clinical parameters. Clin Cancer Res 16: 2409-2417.
21. Pass HI, Levin SM, Harbut MR, Melamed J, Chiriboga L, Donington J, Huflejt M, Carbone M, Chia D, Goodglick L, Goodman GE, Thornquist MD, Liu G, de Perrot M, Tsao MS, Goparaju C (2012) Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma. N Engl J Med 367: 1417-1427.
22. Pinato DJ, Mauri FA, Ramakrishnan R, Wahab L, Lloyd T, Sharma R (2012) Inflammation-based prognostic indices in malignant pleural mesothelioma. J Thorac Oncol 7: 587-594.
23. Proctor MJ, Talwar D, Balmar SM, O'Reilly DSJ, Foulis AK, Horgan PG, Morrison DS, McMillan DC (2010) The relationship between the presence and site of cancer, an inflammation-based prognostic score and biochemical parameters. Initial results of the Glasgow Inflammation Outcome Study. Br J Cancer 103: 870-876.
24. Roxburgh CS, McMillian DC (2010) Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Fut Oncol 6: 149-163.
25. Sarraf KM, Belcher E, Raevsky E, Nicholson AG, Goldstraw P, Lim E (2009) Neutrophil/lymphocyte ratio and its association with survival after complete resection in non-small cell lung cancer. J Thorac Cardiovasc Surg 137: 425-428.
26. Veit-Haibach P, Schaefer N, Steinerta H, Soyka JD, Seifert B, Stahel RA (2010) Combined FDG-PET/CT in response evaluation of malignant pleural mesothelioma. Lung Cancer 67: 311-317.
27. Vogelzang NJ, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer MES, Manegold C, Niyikiza C, Paoletti P (2003) Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 21, pp 2636-2644.
28. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ (2005) Neutrophil- lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol 91: 181-184.
29. Yates DH, Corrin B, Stidolph PN, Browne K (1997) Malignant mesothelioma in south east England: clinicopathological experience of 272 cases. Thorax 52: 507-512.